Board of Directors

APIM Therapeutics's Board of Directors comprises the following members (in addition to Marit Otterlei).

Erlend Skagseth, MBA, Chairman

Erlend Skagseth is currently the Managing Partner at Sarsia Seed Management AS which manages the Sarsia Seed Fund. Erlend brings 25 years of experience from R&D based IPR, project and business development from Christian Michelsen Research, Forinnova and Sarsia Innovation. He has managed several turnaround processes and negotiated a large number of international contracts, licenses and trade exits. He is/has also served as a Board Member in several companies including Avexxin, Vaccibody, Geneseque and others.

Stener Kvinnsland, MD, PhD, Board Member

Dr. Stener Kvinnsland has more than 30 years of experience in oncology. He is currently Chairman of the Board at the Trond Mohn Foundation, the Oslo University Hospital and Helse Stavanger Hf. Among Dr. Kvinnsland’s previous roles, he was Chief Executive Officer of the Bergen Hospital Trust (Helse Bergen), Head of the Department of Oncology and Medical Physics at Haukeland University Hospital, Professor of Medicine (Oncology) at the University of Bergen and Director Clinical R&D, Oncology for Pharmacia & Upjohn in Milan. He was also employed at Oslo Universitetssykehus Hf Chairman) and Health Faculty at Tromso University (Chairman). Dr. Kvinnsland also serves on the Board of BergenBio.

Farzad Abdi-Dezfuli PhD, Board Member

Dr. Abdi-Dezfuli is currently a Partner at Sarsia Seed Management AS. He has a strong background in preclinical and clinical research with extensive drug development experience from Eli Lilly culminating as Team leader medical, Eli Lilly, Norway. He also brings to the Board several years of experience in commercializing innovative medical/biotech projects from the Sarsia investment group. Dr. Abdi-Dezfuli is/has also served as a Board Member or Observer in several companies including Avexxin, BergenBio, Vaccibody and others.

Jørgen André Nilsen, Board Member

Jørgen has more than 20 years of experience in the intersection of entrepreneurship and venture investment. He is an accomplished entrepreneur and the founder of several ICT and energy service companies, both in Norway and the US. He has also worked as an affiliate researcher at the Stanford Research Institute (SRI) Learning on Demand program and worked as a technology advisor for the Norwegian Trade Council in San Francisco. Before joining Televenture Management as partner, he served as Investment Director at the Technology Transfer Office Campus Kjeller AS.

Martin Welschof PhD, Board Member

Dr. Welschof is currently the CEO for BioInvent, Sweden. Martin brings significant senior executive experience in the biotech sector having launched and/or built successful businesses focused on drug development and drug discovery platforms. Before joining BioInvent, Martin Welschof was CEO of Opsona Therapeutics, Managing Director and co-founder of Affitech A/S in Oslo/Norway and Copenhagen/Denmark. Prior to joining Affitech A/S, Dr. Welschof was the Director of Technology at Axaron Bioscience AG, Heidelberg, Germany. During his period at Axaron he worked also in the parent company of Axaron Bioscience, LYNX Therapeutics Inc. in Hayward California. Martin holds a PhD in the field of recombinant antibody technology from the University of Bielefeld, Germany. Martin Welschof also serves at the board of Nextera.

Birgitte Gangmark Villmo, Board Member

Birgitte Gangmark Villmo is currently an Investment Manager at Investinor, the largest Norwegian venture fund and investor in APIM Therapeutics. Birgitte has a Master’s degree in Financial Economics from NTNU and a Master of Finance from Massachusetts Institute of Technology (MIT). Prior to her engagement at Investinor, she formerly worked 5 years at Norges Bank Investment Management (NBIM) as a graduate trainee and analyst, mainly in London where she was also seconded to UBS Investment Bank for one year. Before joining Investinor, Birgitte worked for a shorter period at NTNU and for a real estate company in Chile.

Gökhan Batur, Board Member

Gökhan Batur has more than 18 years of healthcare industry experience. Until recently, he has been the CEO at Polyphor, a publicly traded Swiss Biotechnology company focused to oncology and infectious disease. At Polyphor, he has led a large international Phase 3 trial for the company’s immuno-oncology program with balixafortide in metastatic breast cancer and brought a novel class program in cystic fibrosis from GLP to Phase 1 focusing on treating chronic infections. Before joining Polyphor, he assumed various management roles at Merck Co Inc. known as MSD outside of the US, lastly serving as Executive Director, Global Head, Antibiotics, responsible for leading the entire Merck antibiotics portfolio managing multiple in-line, launch and pipeline products and sales of ~2 billion dollars. Throughout his large pharma and biotech journey, Gokhan brings substantial experience in commercialization, R&D, corporate development, business development and investor relations in companies with strong focus to anti-infectives, rare diseases and oncology. He received his BS in Management Information Systems from Bosphorus University, Istanbul.